Eight Product-Hopping Takeaways from Namenda Ruling

Law360
June.11.2015

Orrick attorneys Rob Reznick, David Goldstein, Richard Goldstein and Howard Ullman co-authored an article on the Second Circuit's affirmation of a preliminary injunction in New York v. Actavis and what aspects of the case may be inapplicable in other settings.

市场洞察

Authors

Robert Reznick 高级顾问律师, 复杂诉讼与争议解决, Antitrust & Competition

Washington, D.C.

See my bio

D:+1 202 339 8409
E: [email protected]

Practice:

Technology & Innovation Sector
Life Sciences Sector
复杂诉讼与争议解决
Antitrust & Competition
知识产权

vCard

See full bio

Robert Reznick 高级顾问律师

Washington, D.C.

He currently is national coordinating counsel for a major oil company in connection with its climate change litigation. He previously served as co-lead counsel to a major international pharmaceutical manufacturer in the defense of nationwide litigation challenging industry pricing practices.

Rob’s experience includes extensive work in antitrust and False Claims Act cases, claims alleging fraud, and agency enforcement actions. His pharmaceutical industry activities include service as outside counsel to and Corporate Secretary of the Pharmaceutical Security Institute, Inc., the industry’s not-for-profit trade organization dedicated to the fight against pharmaceutical counterfeiting.

He is Managing Editor of The World in U.S. Courts, Orrick’s quarterly review of court decisions addressing personal jurisdiction over non-U.S. parties and the extraterritorial application of U.S. law to global business and cross-border activities.

Rob also served two terms on the District of Columbia Bar’s Pro Bono standing committee. Before joining Orrick, he was a partner in Hughes Hubbard & Reed LLP and Clifford & Warnke, in Washington, D.C.